Historical record - last NADAC effective date: 7/17/2024
Product Information
CHOLESTYRAMINE PACKET is a generic product labeled by TAGI Pharma Inc., priced at $0.6370 per EA under NDC 51224001120. Its NADAC has been published 112 times since Jun 29, 2022.
FDA first approved this application on Mar 9, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 g/8.3g
Manufacturer
TAGI Pharma Inc.NDC
51224001120
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
7/17/2024
Active Ingredients
CHOLESTYRAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA209597FDA Approved
3/9/2021
TE Code
AB
On Market Since
3/10/2021
Pharmacological Classes
Price Statistics
The NADAC for CHOLESTYRAMINE PACKET has been published 112 times since Jun 29, 2022, and over the history we have for it it has declined 42.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6370 per EA |
|---|---|
| All-time high | $1.1213 (Aug 10, 2022) |
| All-time low | $0.5806 (Apr 17, 2024) |
| Median price | $0.8997 |
| Average price | $0.8733 |
| Largest weekly change | +34.2% (Jun 19, 2024) |
| Weeks tracked | 112 |
| Tracking since | Jun 29, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-12.1%
5Y
N/A
All
-42.5%
Last surveyed Aug 14, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
TAGI Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cholestyramine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bile Acid Sequestrant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHOLESTYRAMINE PACKET?
The current National Average Drug Acquisition Cost (NADAC) for CHOLESTYRAMINE PACKET, manufactured by TAGI Pharma Inc., is $0.6370 per EA (NDC 51224001120), effective Aug 14, 2024.
How has the price of CHOLESTYRAMINE PACKET changed over time?
Over the history we have for it, the NADAC for CHOLESTYRAMINE PACKET has declined 42.5%. It has been tracked across 112 weekly CMS publications since Jun 29, 2022.
What are the highest and lowest recorded NADAC prices for CHOLESTYRAMINE PACKET?
Since Jun 29, 2022, the NADAC for CHOLESTYRAMINE PACKET has ranged from a low of $0.5806 (Apr 17, 2024) to a high of $1.1213 (Aug 10, 2022), with a median of $0.8997 per EA.
Are there cheaper alternatives to CHOLESTYRAMINE PACKET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CHOLESTYRAMINE PACKET in a comparable dosage form, but none are currently priced below it.
Who manufactures CHOLESTYRAMINE PACKET?
CHOLESTYRAMINE PACKET (NDC 51224001120) is labeled by TAGI Pharma Inc., and CMS classifies it as a generic product.